Kintara Therapeutics Inc

NASDAQ:KTRA   3:59:48 PM EDT
2.24
+0.16 (+7.69%)
Products, Regulatory

Kintara Therapeutics Provides Positive Site Activation Update On GCAR Phase 2/3 Clinical Trial For Glioblastoma

Published: 05/26/2021 12:37 GMT
Kintara Therapeutics Inc (KTRA) - Kintara Therapeutics Provides Positive Site Activation Update on Gcar Phase 2/3 Clinical Trial for Glioblastoma.
Kintara Therapeutics Inc - Val-083 Treatment Arm in Gcar Registrational Phase 2/3 Clinical Trial Activated in 15 U.S. Sites As of May 14, 2021.
Kintara Therapeutics Inc - Gcar Plans to Enroll 150-200 Patients in Kintara Arm of Study at 30 Sites in U.S. and Canada.
Kintara Therapeutics Inc - Potential to Increase Kintara Arm of Study to 40 Clinical Trial Centers.